RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
Taken together, this study provides insight into the role of RANKL/RANK axis in immune tolerance, demonstrates the significant impact of RANKL-dependent impairment of T cell-DC/pDC crosstalk on tumor development and, ultimately, supports that this ligand could be an interesting actionable target for cancer immunotherapy.
Authors
- Thomas Lerho
- Mathieu DM Renard
- Olivier Peulen (ORCID: https://orcid.org/0000-0002-6933-0134)
- Elodie Hendrick
- Philippe Delvenne
- Michaël Herfs (ORCID: https://orcid.org/0000-0002-4382-8997)
- Célia Reynders
- Diane Bruyère
- Marie‐Julie Nokin
- Raphaël Peiffer (ORCID: https://orcid.org/0000-0001-5839-8849)
- Pascale Hubert (ORCID: https://orcid.org/0000-0002-0799-3047)
- Marie Ancion
- Rebekah Crake (ORCID: https://orcid.org/0000-0002-0886-2487)
- Florian Poulain (ORCID: https://orcid.org/0000-0003-2831-3634)
- Patrick Roncarati
- Margaux Luyckx
- Charlotte Pilard
- Alizée Lebeau (ORCID: https://orcid.org/0000-0002-1144-3232)
Institutions
- University of Liège (BE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-010753
- Citations
- 4
- Primary Topic
- NF-κB Signaling Pathways
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Amgen
- Fonds De La Recherche Scientifique - FNRS
- Fonds Léon Fredericq
- Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture